Immunovant director plans sale of 6,000 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Atul Pande, a director of Immunovant, Inc. (IMVT), gave notice covering 6,000 common shares for sale, with an aggregate market value of $214,260 and an approximate sale date of November 11, 2026.
The notice says the shares were and will be received through stock-option exercises over the next three months, with acquisition and payment dates tied to exercise and sale dates. It identifies a Rule 10b5-1 plan adopted December 26, 2025, and Morgan Stanley Smith Barney LLC as broker. Pande's reported sales during the prior three months included 1,500 shares on August 28, 2026, for gross proceeds of $64,905.
Key Figures
Key Terms
Rule 10b5-1 regulatory
Exercise of Stock Options financial
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.